CVS Launches Cordavis To Make US Biosimilars More Accessible, Affordable

First Partner Is Sandoz For Adalimumab Product

CVS Health’s new subsidiary Cordavis will help manufacturers produce and/or commercialize biosimilars with the aim of reducing overall drug costs while improving access to and affordability of medicines.

CVS Health office in Chandler, AZ
CVS will get into biosimilars via subsidiary Cordavis • Source: Shutterstock

Pharmacy giant CVS Health Corp. has launched a wholly owned subsidiary called Cordavis to work directly with manufacturers to commercialize and/or produce biosimilars. The subsidiary will build a portfolio of products with the aim of improving access to biosimilars and affordability in the US. CVS said in its announcement late on 23 August that creating more competition should drive down product prices in the US biosimilar market, which is projected to grow from less than $10bn in 2022 to more than $100bn in 2029.

It remains to be seen whether increased competition in the biosimilar space is the key to boosting overall growth of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

More from Scrip